A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MSW / mutant selection window

[Related PubMed/MEDLINE]
Total Number of Papers: 53
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MSW  (>> Co-occurring Abbreviation)
Long Form:   mutant selection window
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A pilot study on the comparative minimum inhibitory and mutant prevention concentration values for moxifloxacin and pradofloxacin against canine and human isolates of Staphylococcus pseudintermedius and S.schleiferi. CLSI, FQ, MIC, MPC
2019 Mutant selection window of clarithromycin for clinical isolates of Helicobacter pylori. H. pylori, MIC, MPC, TMSW
2019 Mutant selection window of disinfectants for Staphylococcus aureus and Pseudomonas aeruginosa. MDRP, MICs, MPCs, MRSA, MSSA
2018 In vitro activity of minocycline combined with aminoglycosides against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. KPC, MPC
2018 Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates. MPC
2018 Mutant selection window of four quinolone antibiotics against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. MPC, QRDR
2018 Screening method for trimethoprim/sulfamethoxazole-resistant small colony variants of Staphylococcus aureus. MIC, MRSA, SCVs, SXT
2017 Antimicrobial Activity and Resistance: Influencing Factors. ---
2017 Determination of the Mutant Prevention Concentration and the Mutant Selection Window of Topical Antimicrobial Agents against Propionibacterium acnes. MPC
10  2017 Determination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and Valnemulin. MIC99, MPC
11  2017 In Vitro Resistance Selection in Shigella flexneri by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin. AUC, MPC
12  2017 Mechanisms responsible for imipenem resistance among Pseudomonas aeruginosa clinical isolates exposed to imipenem concentrations within the mutant selection window. MPCs
13  2017 Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model. RMs
14  2017 Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study. MPC
15  2016 HIV-1 resistance to neutralizing antibodies: Determination of antibody concentrations leading to escape mutant evolution. HIV-1
16  2016 In vitro susceptibility of four antimicrobials against Riemerella anatipestifer isolates: a comparison of minimum inhibitory concentrations and mutant prevention concentrations for ceftiofur, cefquinome, florfenicol, and tilmicosin. MIC, MPC
17  2016 Molecular Mechanisms of Ceftaroline Susceptibility Reduction in Methicillin-Resistant Staphylococcus aureus. MRSA
18  2016 Mutant prevention concentrations of daptomycin for Enterococcus faecium clinical isolates. MIC, MPC
19  2016 Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria. MPC, PD
20  2016 Tigecycline-Amikacin Combination Effectively Suppresses the Selection of Resistance in Clinical Isolates of KPC-Producing Klebsiella pneumoniae. MIC, MPC
21  2015 Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations. MPC
22  2015 Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models. MPC
23  2015 Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin. MIC99, MPC
24  2014 A correlation between reduced susceptibilities to vancomycin and daptomycin among the MRSA isolates selected in mutant selection window of both vancomycin and daptomycin. MPC
25  2014 In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model. E. coli, MPC
26  2014 Selection and characterisation of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I. MICs, MRSA, MSSA
27  2014 Testing the mutant selection window hypothesis with Escherichia coli exposed to levofloxacin in a rabbit tissue cage infection model. MPC
28  2013 In vitro potency and efficacy favor later generation fluoroquinolones for treatment of canine and feline Escherichia coli uropathogens in the United States. E. coli, FQs, MIC, MPC, UTIs
29  2013 Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance. HPLC, MIC, MPC, MRT, PK
30  2013 Relationships between mutant prevention concentrations and mutation frequencies against enrofloxacin for avian pathogenic Escherichia coli isolates. APEC, MPC
31  2012 Testing the mutant selection window in rabbits infected with methicillin-resistant Staphylococcus aureus exposed to vancomycin. MPC
32  2011 Emergence and spread of antibiotic resistance following exposure to antibiotics. MPC
33  2011 [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. HPLC, MIC, MPC
34  2010 Determination of the mutant selection window for clindamycin, doxycycline, linezolid, moxifloxacin and trimethoprim/sulfamethoxazole against community-associated meticillin-resistant Staphylococcus aureus (MRSA). CA-MRSA, MIC, MPC, MRSA
35  2010 Mutant prevention concentrations of fluoroquinolones against Campylobacter jejuni isolated from chicken. CCCP, FQ, MPC
36  2009 Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae. MPC
37  2009 In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium. AUC, MIC, MPC
38  2009 New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. MIC, MPC
39  2009 Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model. MPC
40  2009 [Mutant prevention concentrations of antibacterial agents to ocular pathogenic bacteria]. CHL, CIP, LVF, MIC, MPC, NCCLS, NFL, OFL, TOB
41  2008 Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. AUC, CIP, MPC
42  2008 Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. MIC, MPC
43  2008 Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline. MPC
44  2008 [Mutant Prevention Concentration: is it significant in the clinical practice?]. MPC
45  2007 In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. MPC, MXF, TB
46  2007 Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection. ---
47  2006 Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. DAP, MPC, VAN
48  2004 Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination. IEK, MPC
49  2004 In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. CART, MIC, MPC
50  2004 Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. expPP, gyrA, LVX, MFX, MPCs
51  2004 Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. MPC
52  2003 Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. MPC
53  2003 In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. AUC, CIP, GAT, LEV, max, MOX, MPC